{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:27:39Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 20.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094f0-526f-7da2-8d30-1ef3342ae420\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: eletriptan\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 86.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094f0-525f-7f01-a59b-37311a2ac0bc\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: eletriptan\nRegistry id: vr.tr.eletriptan\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:56:51+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q415032", "registryId": "vr.tr.eletriptan", "name": "eletriptan", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q415032/", "model": { "registry_id": "vr.tr.eletriptan", "name": "eletriptan", "purpose": "Enable an agent to recognise eletriptan, assess the identity and fitness of a material containing it, and identify the evidence required before handling or using it.", "definition": "Eletriptan is a synthetic triptan drug that acts principally as a serotonin 5-HT1B/1D receptor agonist and is used for the acute treatment of migraine with or without aura in adults.", "scope_statement": "This model owns vr.tr.eletriptan in PHY / PHY.MAT: eletriptan substance identity, material forms, quality, physicochemical state, biological activity and substance-level constraints; salts are related forms with explicit identities, not silently interchangeable substances.", "in_scope": [ "Molecular identity, stereochemistry and verified substance identifiers", "Free-base versus salt identity and eletriptan-equivalent content", "Grade, assay, impurities and analytical evidence for a material lot", "Physical form, condition-dependent properties and stability", "Pharmacological relationships and evidence-linked handling or use constraints" ], "out_of_scope": [ "Finished tablet formulations, excipients, packaging and brand identity", "Patient-specific diagnosis, prescribing and treatment decisions", "Migraine as a disease and triptans as a broader drug class", "Manufacturing equipment and complete synthesis procedures", "Independent models of metabolites, counterions and other active substances" ], "distinguishing_features": [ "Require molecular connectivity to match authenticated eletriptan reference data; being described as a triptan is insufficient.", "Verify the R configuration at the relevant pyrrolidine stereocentre rather than accepting an unspecified stereoisomer. The hydrobromide label identifies this configuration: [DailyMed description](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6dc0893-b845-4f96-e053-6294a90a856f&type=display).", "Determine whether the record describes eletriptan itself or its hydrobromide salt; the label distinguishes salt mass from eletriptan-equivalent mass: [DailyMed composition](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6dc0893-b845-4f96-e053-6294a90a856f&type=display).", "Distinguish parent eletriptan from its N-demethylated metabolite using structural or analytical evidence. The label describes the metabolite separately: [DailyMed metabolism](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6dc0893-b845-4f96-e053-6294a90a856f&type=display).", "Treat a tablet containing eletriptan as a related product, not as a pure eletriptan sample." ], "characteristics": [ { "name": "Verified chemical identity", "kind": "relation", "unit_or_values": "Structure-linked CAS, PubChem CID, EC number and UNII where verified; distinguish unavailable from unverified", "why_it_matters": "Prevents identifiers for a salt, stereoisomer or product from being assigned to the parent substance." }, { "name": "Stereochemical composition", "kind": "measurement", "unit_or_values": "Absolute configuration; enantiomeric purity or enantiomeric excess in %, with method", "why_it_matters": "A connectivity match alone cannot establish the intended stereochemical identity." }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base; hydrobromide; other verified salt; mixture; unresolved, with solvate or hydrate status", "why_it_matters": "Form determines which composition, mass conversion and physical-property evidence applies." }, { "name": "Eletriptan content", "kind": "measurement", "unit_or_values": "mg eletriptan-equivalent/g material or mass %, with as-is, dried or anhydrous basis", "why_it_matters": "Separates active-moiety content from gross salt or sample mass." }, { "name": "Grade and disposition", "kind": "state", "unit_or_values": "Declared grade and governing specification; untested, quarantined, released, rejected or retest required", "why_it_matters": "Identity does not establish suitability for a proposed analytical or pharmaceutical use." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "% or ppm by named analyte, with detection limits and acceptance criteria", "why_it_matters": "Separates chemical purity, stereochemical purity, residual solvents and degradation." }, { "name": "Physical-property evidence", "kind": "measurement", "unit_or_values": "Solubility in mg/mL; thermal events in °C; pKa dimensionless; include form, method and conditions", "why_it_matters": "Prevents values for hydrobromide, solutions or unspecified forms from becoming universal eletriptan constants." }, { "name": "Storage condition", "kind": "state", "unit_or_values": "Temperature in °C, relative humidity in %, light exposure, container condition and excursion history", "why_it_matters": "Connects current material fitness to supporting stability evidence." }, { "name": "Biological activity evidence", "kind": "relation", "unit_or_values": "Receptor, assay type, potency or affinity with units, biological system and source", "why_it_matters": "Keeps receptor binding, functional agonism and clinical effects distinct." }, { "name": "Applicable hazard and regulatory record", "kind": "relation", "unit_or_values": "Form-specific SDS, GHS classification, exposure limit if established, jurisdiction, authority and revision date", "why_it_matters": "Supports handling and supply decisions without treating missing classifications as evidence of safety." } ], "affordances": [ "Resolve a supplied name or identifier to eletriptan and flag salt or stereochemical ambiguity.", "Compare a material lot with an authenticated reference and its intended-use specification.", "Calculate eletriptan-equivalent content when salt stoichiometry, assay and moisture basis are established.", "Select a characterisation or stability check appropriate to the reported material form.", "Flag source-supported pharmacological constraints for review by a linked prescribing workflow.", "Determine whether handling, storage or release is supported by current evidence, or requires further review." ], "agent_conduct": { "may": [ "Identify eletriptan by name, identifiers and documented properties, citing sources.", "Report approved uses, warnings and interactions from official product information.", "Check a material lot's certificate of analysis against its specification." ], "must_not": [ "Recommend it or a dose for a particular person's migraine.", "Downplay warnings for people with heart or blood vessel disease.", "Supply it outside lawful pharmaceutical channels.", "Present it as a preventive treatment when it is for acute attacks." ], "requires_human": [ "Any decision to start or change a patient's migraine treatment.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Migraine is disabling; patients need honest information about benefits and heart risks." ], "affected_parties": [ "People with migraine", "Prescribers and pharmacists" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance." ], "failure_modes_and_hazards": [ "Narrowing of blood vessels, a risk in heart and vascular disease.", "Interactions with drugs that block its breakdown.", "Medication overuse headache with frequent use." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "Eletriptan is encountered in pharmaceutical materials and medicines used for the acute treatment of migraine attacks in adults.", "It is also used in analytical and pharmacological research concerning triptan identity, quality and activity.", "Assessment of a material containing eletriptan depends on its chemical form, formulation, provenance and intended use." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q415032: eletriptan", "url": "https://www.wikidata.org/wiki/Q415032", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Eletriptan", "url": "https://en.wikipedia.org/wiki/Eletriptan", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "eletriptan-identity", "name": "Eletriptan identity", "description": "Establish the molecular and registry identity of the substance.", "rationale": "A triptan name, salt label or analytical peak alone cannot establish that a record denotes eletriptan.", "layers": [ { "id": "structure-and-stereochemistry", "name": "Structure and stereochemistry", "description": "Resolve connectivity and stereochemical specificity against authenticated evidence.", "findings": [ { "id": "authenticated-structure-match", "name": "Authenticated structure match", "description": "Require identity evidence that distinguishes eletriptan from stereoisomers, related triptans and modified derivatives.", "questions": [ { "text": "Which authenticated structure and stereochemical representation define eletriptan for this record?", "kind": "definition", "id": "authenticated-structure-match-q01" }, { "text": "Which orthogonal analytical results establish connectivity and stereochemical agreement with the reference?", "kind": "measurement", "id": "authenticated-structure-match-q02" } ] } ] }, { "id": "registry-and-form-boundaries", "name": "Registry and form boundaries", "description": "Resolve identifiers without duplicating the registered concept.", "findings": [ { "id": "parent-and-salt-mapping", "name": "Parent and salt mapping", "description": "Map each external identifier to its exact chemical entity and relate salts to the parent registry entry.", "questions": [ { "text": "Which verified CAS, PubChem, EC and UNII records identify the parent, and which identify hydrobromide or another form?", "kind": "provenance", "id": "parent-and-salt-mapping-q01" }, { "text": "Does an existing Vercy world model already own this concept, requiring a link instead of a second publication?", "kind": "boundary", "id": "parent-and-salt-mapping-q02" } ] } ] } ] }, { "id": "eletriptan-material-quality", "name": "Eletriptan material quality", "description": "Determine what a supplied material contains and whether its quality supports the proposed use.", "rationale": "Salt mass, active-moiety content and analytical purity answer different questions.", "layers": [ { "id": "composition-and-content", "name": "Composition and content", "description": "Establish form, stoichiometry and assay basis before comparing quantities.", "findings": [ { "id": "eletriptan-equivalent-basis", "name": "Eletriptan-equivalent basis", "description": "Make salt identity, water or solvent content and assay corrections explicit in any conversion to eletriptan-equivalent mass.", "questions": [ { "text": "What salt stoichiometry, hydration or solvation state and assay basis apply to this material?", "kind": "measurement", "id": "eletriptan-equivalent-basis-q01" }, { "text": "What verified conversion yields eletriptan-equivalent content from the measured material mass?", "kind": "action", "id": "eletriptan-equivalent-basis-q02" } ] } ] }, { "id": "impurities-and-release", "name": "Impurities and release", "description": "Assess lot-specific analytical evidence against a named specification.", "findings": [ { "id": "use-specific-quality-decision", "name": "Use-specific quality decision", "description": "Keep identity, assay, enantiomeric purity and impurity acceptance separately reviewable.", "questions": [ { "text": "Which methods quantify opposite-enantiomer content, related substances, residual solvents and degradation products?", "kind": "measurement", "id": "use-specific-quality-decision-q01" }, { "text": "Which approved specification and certificate support release for the intended use, and what remains untested?", "kind": "action", "id": "use-specific-quality-decision-q02" } ] } ] } ] }, { "id": "eletriptan-physical-state", "name": "Eletriptan physical state", "description": "Record the material form and conditions governing physical behaviour and preservation.", "rationale": "Measurements for a particular salt or solid form cannot automatically describe every eletriptan material.", "layers": [ { "id": "form-dependent-properties", "name": "Form-dependent properties", "description": "Attach measured constants to the tested form and experimental conditions.", "findings": [ { "id": "qualified-property-values", "name": "Qualified property values", "description": "Record phase, solid-form evidence, solubility and thermal behaviour without inventing missing constants.", "questions": [ { "text": "Which free-base or salt form was tested, and what establishes its crystalline, amorphous or solution state?", "kind": "measurement", "id": "qualified-property-values-q01" }, { "text": "What solubility, melting, boiling or decomposition evidence is available with temperature, pressure, pH and method as applicable?", "kind": "measurement", "id": "qualified-property-values-q02" } ] } ] }, { "id": "stability-and-storage", "name": "Stability and storage", "description": "Relate storage history to material-specific stability evidence.", "findings": [ { "id": "supported-storage-disposition", "name": "Supported storage disposition", "description": "Require evidence for bulk-material storage and retest decisions rather than importing finished-tablet shelf life.", "questions": [ { "text": "Which stability studies establish sensitivity to heat, moisture, light or solution conditions for this form?", "kind": "provenance", "id": "supported-storage-disposition-q01" }, { "text": "Does the lot's exposure history require retesting, quarantine or rejection under its governing specification?", "kind": "action", "id": "supported-storage-disposition-q02" } ] } ] } ] }, { "id": "eletriptan-biological-relations", "name": "Eletriptan biological relations", "description": "Represent receptor activity, metabolism and interaction evidence at substance level.", "rationale": "These relations distinguish pharmacological behaviour while leaving individual treatment decisions to clinical models.", "layers": [ { "id": "receptor-activity", "name": "Receptor activity", "description": "Separate measured receptor binding from functional and therapeutic interpretations.", "findings": [ { "id": "binding-versus-agonism", "name": "Binding versus agonism", "description": "The label describes 5-HT1B/1D agonism and binding to additional receptor subtypes; these are distinct evidence types. [DailyMed pharmacology](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6dc0893-b845-4f96-e053-6294a90a856f&type=display).", "questions": [ { "text": "Which receptor-specific results measure affinity, and which demonstrate functional agonism?", "kind": "measurement", "id": "binding-versus-agonism-q01" }, { "text": "What assay system, concentration range and source support each activity claim?", "kind": "provenance", "id": "binding-versus-agonism-q02" } ] } ] }, { "id": "metabolism-and-interactions", "name": "Metabolism and interactions", "description": "Link parent-substance disposition to metabolism and interaction evidence.", "findings": [ { "id": "cyp3a4-dependent-exposure", "name": "CYP3A4-dependent exposure", "description": "The label identifies CYP3A4 as the primary metabolic pathway and reports increased exposure with potent inhibitors. [DailyMed metabolism and interactions](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6dc0893-b845-4f96-e053-6294a90a856f&type=display).", "questions": [ { "text": "Which studies establish CYP3A4 involvement and quantify exposure changes under specified conditions?", "kind": "provenance", "id": "cyp3a4-dependent-exposure-q01" }, { "text": "Which current interaction constraints must a linked clinical workflow consult before evaluating a proposed use?", "kind": "action", "id": "cyp3a4-dependent-exposure-q02" } ] } ] } ] }, { "id": "eletriptan-handling-and-authority", "name": "Eletriptan handling and authority", "description": "Connect exact material identity to applicable handling evidence and authorised-use records.", "rationale": "Bulk chemical hazards and medicinal-product permissions require different evidence and must remain distinguishable.", "layers": [ { "id": "bulk-material-hazards", "name": "Bulk material hazards", "description": "Determine protections and disposal requirements for the actual supplied form.", "findings": [ { "id": "form-specific-hazard-evidence", "name": "Form-specific hazard evidence", "description": "Use an applicable SDS and exposure assessment; clinical adverse effects do not establish a GHS classification.", "questions": [ { "text": "Which current SDS covers this form, grade and supplier, and what classifications or exposure limits does it substantiate?", "kind": "provenance", "id": "form-specific-hazard-evidence-q01" }, { "text": "What containment, protective equipment, spill response and disposal requirements follow for the planned quantity and operation?", "kind": "action", "id": "form-specific-hazard-evidence-q02" } ] } ] }, { "id": "jurisdiction-and-product-links", "name": "Jurisdiction and product links", "description": "Locate applicable authority records without transferring product approval to arbitrary material.", "findings": [ { "id": "bounded-authorisation", "name": "Bounded authorisation", "description": "Record which substance form, product, activity and jurisdiction an authorisation actually covers.", "questions": [ { "text": "Which current authority record governs the intended jurisdiction and activity involving this eletriptan material?", "kind": "provenance", "id": "bounded-authorisation-q01" }, { "text": "Which permissions and restrictions belong to the substance, and which belong to a particular finished product or clinical use?", "kind": "boundary", "id": "bounded-authorisation-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information; no sources were consulted.", "Verify CAS and PubChem identifiers separately for the free base and hydrobromide salt.", "Check current jurisdiction-specific labeling for contraindications and interactions, and substance-specific data for purity, physical constants and chemical hazard classification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Eletriptan free base", "Eletriptan hydrobromide" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "WHO Anatomical Therapeutic Chemical classification", "value_or_pattern": "N02CC06", "note": "Classification code for eletriptan." }, { "scheme": "Molecular formula", "value_or_pattern": "C22H26N2O2S", "note": "Formula of the free base; the hydrobromide salt has a different composition." }, { "scheme": "International Nonproprietary Name", "value_or_pattern": "eletriptan", "note": "Names the active substance rather than a particular tablet product." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Acute treatment of migraine attacks with or without aura in adults.", "Formulation as oral tablets containing eletriptan hydrobromide." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of eletriptan free base", "typical_range": "382.52", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Vasoconstrictive effects create risks in people with certain cardiovascular or cerebrovascular diseases.", "Potent CYP3A4 inhibitors can increase eletriptan exposure.", "Combining it with other triptans or ergot derivatives can increase vasospastic risk.", "Serotonin syndrome is a potential hazard, particularly with other serotonergic medicines.", "Frequent use of acute migraine medicines can contribute to medication-overuse headache." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, product availability, strengths and prescribing restrictions depend on the jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Eletriptan hydrobromide", "difference": "The hydrobromide is a salt of eletriptan; salt identity changes formula and molar mass." }, { "name": "Sumatriptan", "difference": "A distinct triptan molecule with different substituents and pharmacokinetic properties." }, { "name": "Relpax", "difference": "A branded medicinal product containing eletriptan rather than the chemical substance itself." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of eletriptan this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative identifiers and existing Vercy publications resolve the parent eletriptan entry without duplicating a salt or an existing model?", "Which validated specifications and analytical methods establish acceptable assay, enantiomeric purity and impurity limits for each intended grade?", "What reliable form-specific data establish solid forms, pKa, solubility, thermal behaviour and storage stability, and which requested constants are unavailable or inapplicable?", "Which current SDS classifications, occupational exposure limits and disposal requirements apply to the exact supplied form and jurisdiction?", "Which primary pharmacology studies and current authority records support the biological relations and use constraints beyond the product label consulted?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }